Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 04:30PM GMT
Release Date Price: $70.53 (-2.31%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Thanks, everyone, for joining us. This is the fireside chat with Incyte. My name is Vikram Purohit. I'm one of the Biotech Analyst for the Morgan Stanley Research. Let me read a brief disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.

With that, very happy to have with me Herve Hoppenot, CEO; and Christiana Stamoulis, CFO from Incyte, thanks for joining us.

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

Thank you for having us.

Questions & Answers

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Of course, of course. Herve, Christiana just to start off with, could you provide some opening remarks on the current state of the business and just recap for us what do you think some of the key milestones are that Incyte

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot